Less Ads, More Data, More Tools Register for FREE

Pin to quick picksXaar Regulatory News (XAR)

Share Price Information for Xaar (XAR)

Share Price is delayed by 15 minutes
Get Live Data
145.00    3.00 (2.11%)
Bid:
140.50
Ask:
144.50
Spread: 4.00 (2.847%)
Market Cap: £113.79m
XAR Live PriceLast checked at - London Stock Exchange

Intraday Xaar Share Chart

Trading Update

12 Jan 2023 07:00

RNS Number : 4516M
Xaar PLC
12 January 2023
 

 

 

XAAR plc 

 

TRADING UPDATE

 

Xaar plc ("Xaar", "the Group" or "the Company"), the leading inkjet printing technology group, today announces a trading update for the year ended 31 December 2022.

 

TRADING

Strong revenue growth and full-year profitability

· Revenue for the period is expected to be approximately £74 million (2021: £59.3 million), representing year on year growth of 24% driven by a combination of organic growth (9%) and acquisitions

 

· The Group is expected to deliver an on track adjusted profit for the year

 

· During 2022 the Group continued to invest in working capital and infrastructure development and in March completed the acquisition of Megnajet

 

 

Further operational and strategic progress

· Further progress was made throughout the year in implementing the strategy to achieve long-term profitable growth

 

· Successful launch of Aqueous printhead product in November 2022 as planned, and on budget, is receiving strong customer engagement

 

· Factory reorganisation commenced in December and is progressing well and on schedule for completion by March 2023. This project is expected to deliver increased efficiency, reduce power usage, and reduce costs

 

· The integration of recent acquisitions (FFEI and Megnajet) has been completed successfully and both are contributing positively to Group results 

 

· Continued progress at EPS delivered its best performance to date with revenue growth of 36%

 

 

Challenging macro conditions expected to continue into 2023

· Sales volumes in the Printhead business continue to be affected by the uncertainty in China, which is expected to continue in the short term as Covid cases increase. At this stage it remains unclear when normal levels of business will return

 

· We have maintained our policy of increased investment in inventory to ensure availability of product during the factory reorganisation in Q1 2023 and the remainder of the year

 

BALANCE SHEET AND LIQUIDITY

· The Group remains well capitalised with a strong balance sheet with a net cash position as at 31 December 2022 of £8.6 million

 

 

John Mills, Chief Executive Officer, commented:

"I am hugely proud of the team in delivering a strong performance and making further progress with our strategy. We expect to deliver strong profitable revenue growth and the important milestone of achieving full year profitability representing great progress against our plan and remain well positioned for the business to achieve its exciting potential.

Aquinox has been successfully launched and is already being well received by our customers. With the operational improvements now well underway, notwithstanding the challenging external environment, the business is in good shape to continue to make further progress over the long term."

 

 

 

 

 

 

 

 

 

 

Enquiries:

 

Xaar plc

+44 (0) 1223 423 663 

Ian Tichias, Chief Financial Officer

John Mills, Chief Executive Officer

 

Tulchan Communications

Giles Kernick

Olivia Lucas

+44 (0) 207 353 4200

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTSFIFWFEDSEDF
Date   Source Headline
2nd Jun 202612:58 pmRNSTotal Voting Rights
28th May 20269:18 amRNSResult of AGM
6th May 20267:00 amRNSDirector/PDMR Shareholding
5th May 202611:36 amRNSHolding(s) in Company
30th Apr 20264:44 pmRNSHolding(s) in Company
16th Apr 20269:00 amRNSPublication of Annual Report and Notice of AGM
1st Apr 20263:43 pmRNSHolding(s) in Company
24th Mar 20267:05 amRNSFinal Results
23rd Mar 20263:33 pmRNS-RInvestor Presentation via Investor Meet Company
2nd Mar 20262:44 pmRNSTotal Voting Rights
14th Jan 20267:00 amRNSTrading Statement
5th Jan 202612:28 pmRNSTotal Voting Rights
5th Dec 20251:15 pmRNSHolding(s) in Company
1st Dec 202512:15 pmRNSTotal Voting Rights
24th Nov 202511:00 amRNSDirector/PDMR Shareholding
3rd Nov 20252:00 pmRNSTotal Voting Rights
21st Oct 20254:15 pmRNSDirector/PDMR Shareholding
13th Oct 20253:20 pmRNSHolding(s) in Company
2nd Oct 202511:10 amRNSDirector/PDMR Shareholding
2nd Oct 20258:50 amRNSDirector/PDMR Shareholding
1st Oct 20255:00 pmRNSDirector/PDMR Shareholding
1st Oct 20253:30 pmRNSTotal Voting Rights
1st Oct 202512:04 pmRNSTRADING UPDATE and NOTICE OF RESULTS
1st Sep 20254:30 pmRNSTotal Voting Rights
12th Aug 20257:00 amRNS2025 INTERIM RESULTS
5th Aug 20257:00 amRNSBoard changes
1st Aug 20253:45 pmRNSTotal Voting Rights
14th Jul 202510:00 amRNSNotice of Interim Results
7th Jul 20253:30 pmRNSBlock listing Interim Review
2nd Jul 20253:30 pmRNSTotal Voting Rights
30th Jun 20252:00 pmRNSDirector/PDMR Shareholding
3rd Jun 202510:00 amRNSTotal Voting Rights
28th May 20253:30 pmRNSResult of AGM
21st May 20251:00 pmRNSHolding(s) in Company
7th May 20253:30 pmRNSNotification of Transactions of Directors & PDMRs
2nd May 202510:30 amRNSTotal Voting Rights
15th Apr 20251:15 pmRNS2024 Annual Report and Notice of AGM
11th Apr 202512:00 pmRNSHolding(s) in Company
1st Apr 20254:15 pmRNSHolding(s) in Company
1st Apr 20253:30 pmRNSTotal Voting Rights
31st Mar 20253:45 pmRNSNotification of Transactions of Directors & PDMRs
31st Mar 20251:10 pmRNSHolding(s) in Company
28th Mar 202511:30 amRNSHolding(s) in Company
27th Mar 202511:00 amRNSHolding(s) in Company
25th Mar 20255:00 pmRNSNotification of Transactions of Directors & PDMRs
25th Mar 20257:00 amRNSFinal Results
5th Mar 202511:30 amRNSTotal Voting Rights
19th Feb 202510:30 amRNSHolding(s) in Company
10th Feb 202511:00 amRNSHolding(s) in Company
5th Feb 20254:00 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.